The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 08, 2023

Filed:

Oct. 26, 2017
Applicant:

Longhorn Vaccines and Diagnostics, Llc, Bethesda, MD (US);

Inventors:

Gerald W. Fischer, Bethesda, MD (US);

Richard F. Schuman, Boyds, MD (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/48 (2006.01); A61P 31/06 (2006.01); A61P 31/08 (2006.01); A61L 29/16 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61P 31/00 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61L 31/16 (2006.01); C12N 9/64 (2006.01);
U.S. Cl.
CPC ...
A61K 38/4886 (2013.01); A61K 9/0073 (2013.01); A61K 9/16 (2013.01); A61K 9/50 (2013.01); A61K 45/06 (2013.01); A61L 29/16 (2013.01); A61L 31/16 (2013.01); A61P 31/00 (2018.01); A61P 31/06 (2018.01); C12N 9/6489 (2013.01); A61L 2300/254 (2013.01); A61L 2300/404 (2013.01); A61L 2300/45 (2013.01); C12Y 304/24075 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles.


Find Patent Forward Citations

Loading…